



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 12th November 2021

Re: Freedom of Information Request 314-2021

Thank you for your email dated the 20th October 2021, requesting information in relation to Breast Cancer.

The information that you require is as follows:

Please note, in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies listed below?

- **Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent Information not held - We only record this information if this is the first intervention at our Trust**
- **Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) = Exempt under S.40**
- **Abemaciclib + Fulvestrant = 23 patients**
- **Anthracycline (e.g. doxorubicin or epirubicin) as a single agent = 6 patients**

- Atezolizumab +Nab-paclitaxel/Paclitaxel = 6 patients
- Capecitabine as a single agent = 55 patients
- Carboplatin or Cisplatin as a single agent = Exempt under S.40
- Eribulin as a single agent or in combination = 17 patients
- Everolimus + Exemestane = 0 patients
- Fluorouracil = 0 patients
- Fulvestrant as a single agent = 48 patients
- Goserelin = 302 patients
- Lapatinib = 0 patients
- Neratinib = 13 patients
- Olaparib = 0 patients
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) = Exempt under S.40
- Palbociclib + Fulvestrant = 41 patients
- Pertuzumab + Trastuzumab + Docetaxel = 9 patients
- Platinum (e.g. carboplatin or cisplatin) as a single agent = Exempt under S.40
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) = 0 patients
- Ribociclib + Fulvestrant = Exempt under S.40
- Talazoparib = 1 patient
- Tamoxifen - Information not held - We only record this information if this is the first intervention at our Trust
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent = 137 patients
- Transtuzumab as a single agent = 131 patients
- Trastuzumab emtansine = 71 patients
- Transtuzumab deruxtecan = 12 patients
- Any other active systemic anti-cancer therapy

Other	No.
Palbociclib	238
Phesgo	113
EC	95
Paclitaxel / EC	46
Paclitaxel+Pertuzumab+Trastuz	35
Abemaciclib	22
Carboplatin + Paclitaxel / EC	21
Paclitaxel / Trastuzumab	21

Carboplatin + Paclitaxel	15
Pertuzumab + Trastuzumab	15
EC / Paclitaxel+Pertuzumab+Trastuz	11
Paclitaxel+Pertuzumab+Trastuz / Phesgo	10
Everolimus	9
Vinorelbine	8
Ribociclib	6
Cyclophosphamide + Docetaxel	= Exempt under S.40
GemCarbo	= Exempt under S.40
Phesgo / Paclitaxel albumin (Abraxane)	= Exempt under S.40
Trastuzumab / Paclitaxel	= Exempt under S.40
Paclitaxel+Pertuzumab+Trastuz / Phesgo / Trastuzumab(Kadcyla®)	= Exempt under S.40
Paclitaxel+Pertuzumab+Trastuz / Paclitaxel albumin (Abraxane) / Phesgo	= Exempt under S.40
Trastuzumab / Trastuzumab(Kadcyla®)	= Exempt under S.40
EC / Docetaxel	= Exempt under S.40
Paclitaxel / Paclitaxel albumin (Abraxane)	= Exempt under S.40
Paclitaxel / Phesgo	= Exempt under S.40
AC	= Exempt under S.40
Atezolizumab	= Exempt under S.40
EC / Phesgo	= Exempt under S.40
Phesgo/Faslodex	= Exempt under S.40
Phesgo / Trastuzumab / (Kadcyla®)	= Exempt under S.40
Paclitaxel albumin (Abraxane) / EC	= Exempt under S.40
Paclitaxel+Pertuzumab+Trastuz / Trastuzumab(Kadcyla®)	= Exempt under S.40
EC / Paclitaxel + Phesgo / Paclitaxel+Pertuzumab+Trastuz	= Exempt under S.40
Faslodex / Trastuzumab	= Exempt under S.40
Trastuzumab / Phesgo	= Exempt under S.40
Phesgo / Trastuzumab / Trastuzumab(Kadcyla®)	= Exempt under S.40
Paclitaxel+Pertuzumab+Trastuz / Trastuzumab	= Exempt under S.40
Carboplatin + Paclitaxel / Carboplatin Paclitaxel albumin (Abraxane) / EC	= Exempt under S.40
Ibrandronate	= Exempt under S.40
Epirubicin CMF	= Exempt under S.40
Pertuzumab + Trastuzumab / Trastuzumab(Kadcyla®)	= Exempt under S.40
Trastuzumab / Ibandronate	= Exempt under S.40
TCH / Trastuzumab	= Exempt under S.40
Phesgo / Trastuzumab(Kadcyla®)	= Exempt under S.40
EC / Paclitaxel / Phesgo / Paclitaxel albumin (Abraxane)	= Exempt under S.40
Docetaxel / Trastuzumab	= Exempt under S.40
Paclitaxel / Capecitabine	= Exempt under S.40

EC / Paclitaxel / Paclitaxel albumin (Abraxane)	= Exempt under S.40
Paclitaxel Carboplatin	= Exempt under S.40

Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent?

Information not held - We only record this information if this is the first intervention at our Trust.

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY.

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>

Kind regards

Margaret Moore
Information Governance Administrator
Contact Email: ccf-tr.foi@nhs.net